Companies · Other Health Care
FREMONT · Other Health Care
Diligence memoA one-page analyst read on Nitinol Devices & Components, Inc. — recommendation, valuation, rhythm, risks.→Nitinol Devices & Components, Inc. looks fair against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Nitinol Devices & Components, Inc. is one of 5377 Other Health Care companies tracked from FREMONT. By capital raised it ranks among the largest (ahead of 93% of sector peers), and among the largest by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 20%.
Round size and date are reported; the stage label is inferred from round size (latest is Series C — a $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 93% of sector peers (real $). Modeled value above 98% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #13 of 40.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Specialty Networks, LLC | Series C | $94.5M | $2.2B | 2.08× |
| New MMI Holdings, Inc. | Series C | $80.7M | $1.8B | 1.77× |
| BioMatrix Holdings, L.L.C. | Series C | $80.0M | $1.8B | 1.76× |
| Sea Hunter Holdings, LLC | Series C | $76.3M | $1.7B | 1.68× |
| Bind Benefits, Inc. | Series C | $70.0M | $1.6B | 1.54× |
| Endotronix Inc | Series C | $116.1M | $1.6B | 1.52× |
| Great Basin Scientific, Inc. | Series C | $124.3M | $1.6B | 1.49× |
| TransMedics, Inc. | Series C | $249.0M | $1.5B | 1.40× |
| Landmark Health, LLC | Series C | $90.8M | $1.4B | 1.34× |
| Rapid Micro Biosystems, Inc. | Series C | $134.6M | $1.4B | 1.32× |
| Mdp Acm Holdings, Llc | Series C | $60.0M | $1.4B | 1.32× |
| ACON BioMatrix Investors I, L.L.C. | Series C | $57.5M | $1.3B | 1.26× |
| Nitinol Devices & Components, Inc. this company | Series C | $55.7M | $1.3B | 1.23× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series C | $55.7M | 2016-08-08 | $371.6M | $1.3B | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Richard A. Charpie | — | 1 other | 2016-08 |
| Dean W. Schauer | — | — | 2016-08 |
| Dieter W. Stoeckel | — | — | 2016-08 |
| Jared Bartok | — | — | 2016-08 |
| John W. Fruth | — | — | 2016-08 |
| Thomas W. Duerig | — | — | 2016-08 |
Nitinol Devices & Components, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Homecare Homebase, LLC | Other Health Care | Series C | $56.5M | $1.3B | same sector · same stage |
| Envision Topco Holdings, LLC | Other Health Care | Series C | $54.8M | $1.3B | same sector · same stage |
| Research Imaging Company, LLC | Other Health Care | Series C | $57.5M | $679.4M | same sector · same stage |
| ACON BioMatrix Investors I, L.L.C. | Other Health Care | Series C | $57.5M | $1.3B | same sector · same stage |
| Gentiva Health Services Inc | Other Health Care | Series C | $53.8M | $1.2B | same sector · same stage |
| Afferent Pharmaceuticals, Inc. | Other Health Care | Series C | $58.1M | $1.3B | same sector · same stage |
| Geneoscopy, Inc. | Other Health Care | Series C | $58.4M | $926.6M | same sector · same stage |
| ICC Holdings, LLC | Other Health Care | Series C | $52.6M | $1.0B | same sector · same stage |
See where Nitinol Devices & Components, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Nitinol Devices & Components, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.